3 Reasons Older Adults Are Missing From Drug Trials
Experts say seniors are often excluded from research, leaving physicians to prescribe medications without knowing how they affect aging bodies.
By William Turner ·
Older adults are frequently excluded from clinical trials, a gap that leaves many seniors taking medications that have never been tested on people of their age. Dr. Rhea Rogers, a board-certified physician, explained that this omission creates a specific risk. Because medication metabolizes differently in older communities compared to younger ones, seniors are often walking blind without data to guide their doctors. Gerontologist Sam Cradduck noted that without this participation, new medicines are developed without understanding how they affect the very population most likely to need them.
Many patients view clinical trials as a last resort, a step to take only when other options have failed. Rogers said this perspective misses a major benefit of participation. Joining a study provides immediate access to tomorrow’s medicines, devices, and therapies. These treatments are often years away from becoming available to the general public. By entering a trial, a patient can receive these cutting-edge interventions today rather than waiting for the standard release timeline.
The process of finding and joining a trial requires a shift in how patients evaluate the research. Rogers advised participants to stop asking if the trial will help them individually. Instead, they should ask what scientific question the study is trying to answer. This approach helps ensure the trial aligns with the patient’s medical goals. Prospective participants can search for studies at ClinicalTrials.gov, ask their physicians for recommendations, or contact academic centers and disease-specific organizations that run their own research programs.
Participants should also understand the mechanics of the study before enrolling. Aging expert Amy O’Rourke warned that patients may receive a placebo rather than the experimental drug. She said this expectation should be set going in so patients are not disappointed if they do not see immediate improvement. The National Institutes of Health maintains a list of clinical trials and indicates which ones offer compensation to participants. Some trials pay for gas and other expenses, while others provide direct payment for time spent in the study.
Beyond the medical treatment, participants often gain access to a support network. O’Rourke said she has seen clients form strong connections through local clinical trial groups. These groups include social workers and support circles that connect patients with community resources they did not previously know about. This social support is a major value for older adults who may feel isolated during their treatment process. The experience often leaves participants feeling hopeful and connected to their community.
Concerns about being a guinea pig are common among potential participants. Cradduck addressed this fear by explaining the rigor of the process. By the time a drug reaches the clinical trial stage, it has been thoroughly tested repeatedly. She noted that adverse effects are possible with any prescription, but the trial structure is designed to manage those risks. New medicines cannot be approved for the market without undergoing these clinical trials. If the medical community wants new treatments and new hope for patients, these studies must continue to include diverse age groups.
